Beyond Meat, Viking Therapeutics, Novavax, Baidu, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Portfolio Pulse from Benzinga Neuro
Beyond Meat, Viking Therapeutics, Novavax, Baidu, and Tesla were among the top stocks on investors' radars, with varied performances. Beyond Meat reported Q4 revenues beating estimates, Viking Therapeutics surged after promising Phase 2 data, Novavax is awaited for its quarterly earnings, Baidu is expected to report positive EPS, and Tesla saw a modest increase amid speculation and comments from Jim Cramer.
February 28, 2024 | 2:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baidu rose 1.60% to $112.36, with expectations for an EPS of $2.48 in its upcoming quarterly earnings.
Baidu's stock increase can be attributed to the positive expectations for its upcoming quarterly earnings report, with an anticipated EPS of $2.48.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Beyond Meat reported Q4 revenues of $73.7M, beating estimates despite a year-over-year decrease, closing up 0.94% at $7.52.
The positive revenue report despite a year-over-year decrease and discussions around earnings miss and business reset likely contributed to investor interest and the stock's uptick.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Novavax increased by 9.45%, closing at $6.02, as investors await its quarterly earnings report with an expected EPS of $-0.50.
The anticipation of Novavax's quarterly earnings report and the expected EPS have likely contributed to the stock's increase and investor interest.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 85
POSITIVE IMPACT
Tesla saw a modest increase of 0.17%, closing at $199.73, amid speculation about a mystery buyer and comments from Jim Cramer.
Tesla's slight stock price increase is likely influenced by speculation about a mystery buyer and public comments from figures like Jim Cramer, keeping the company's future prospects in the spotlight.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 75
POSITIVE IMPACT
Viking Therapeutics surged 121.02% to $85.05 after releasing promising Phase 2 data for its weight-loss drug VK2735.
The significant surge in Viking Therapeutics' stock price can be attributed to the positive Phase 2 data for its weight-loss drug, marking a major milestone for the company.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100